Converge Bio

Converge Bio is a generative-AI platform for life sciences that accelerates drug development across discovery, molecular design, and manufacturing. It trains Bio-LLM foundation models directly on biological languages (DNA, RNA, and protein sequences) and delivers them through the Converge Computational Lab, whose applications include ConvergeAB (AI antibody design across IgG/VHH/bispecific formats), ConvergeGEO (protein gene-expression optimization across CHO/HEK293/E. coli and other cell systems), ConvergeCELL (virtual cell simulation for target and biomarker discovery), and a Patent Extractor for mining antibody sequences. The platform is delivered to biotech and pharmaceutical customers under a Request Access engagement model; there is no public developer API, SDK, or self-serve documentation surface today. Backed by Bessemer Venture Partners ($25M Series A, January 2026); founded 2023.

Converge Bio is profiled on the APIs.io network. Tagged areas include Company, Ai Ml, Drug Discovery, Generative AI, and Biotech.

Converge Bio’s developer surface includes engineering blog, support, and 6 more developer resources.

🌐 Visit website 📡 Source on GitHub

15.6/100 emerging ▬ flat Agent 0/100 human only Full breakdown ↓
scored 2026-07-27 · rubric v0.5

AccessApproval

0 APIs

CompanyAi MlDrug DiscoveryGenerative AIBiotechPharmaceuticalAntibody DesignGenomicsLife SciencesMachine Learning

Kin Score

Kin Score How this is scored →
scored 2026-07-27 · rubric v0.5

Composite quality — 15.6/100 · emerging

Contract Quality 0.0 / 25

Developer Ergonomics 1.3 / 20

Commercial Clarity 4.2 / 20

Operational Transparency 0.7 / 13

Governance 0.0 / 12

Discoverability 6.8 / 10

Agent readiness — 0/100 · human only

Machine-Readable Contract 0 / 18

Agentic Access Contract 0 / 15

MCP Server 0 / 12

Machine-Readable Auth 0 / 10

Idempotency 0 / 9

Stable Error Semantics 0 / 8

Request/Response Examples 0 / 7

Rate-Limit Signaling 0 / 7

Typed Event Surface 0 / 6

Agent Skills 0 / 5

Well-Known Catalog 0 / 4

Consent & Bot Identity 0 / 3

Improve this rating by publishing the missing artifacts — every area above can be raised, and the full rubric is at apis.io/rating/. This rating is computed from github.com/api-evangelist/converge-bio: open an issue to ask a question, or submit a pull request to add artifacts. Want it done for you? Prioritized profiling — $2,500 →

Agent Surfaces 1

MCP servers, agent skills, and machine-readable catalogs

LLMsTxt

LLMsTxt

Build 1

SDKs, sample code, and the tooling you integrate with

GitHubOrganization

GitHubOrganization

Access & Security 1

Authentication, authorization, and security posture

DomainSecurity

DomainSecurity

Operate 1

Status, limits, changes, and where to get help

Support

Support

Commercial 2

Pricing, plans, and the legal terms of use

TermsOfService

TermsOfService

PrivacyPolicy

PrivacyPolicy

Company 2

The organization behind the API

Website

Website

Blog

Blog

Source (apis.yml)

aid: converge-bio
name: Converge Bio
description: Converge Bio is a generative-AI platform for life sciences that accelerates drug development across discovery,
  molecular design, and manufacturing. It trains Bio-LLM foundation models directly on biological languages (DNA, RNA, and
  protein sequences) and delivers them through the Converge Computational Lab, whose applications include ConvergeAB (AI antibody
  design across IgG/VHH/bispecific formats), ConvergeGEO (protein gene-expression optimization across CHO/HEK293/E. coli and
  other cell systems), ConvergeCELL (virtual cell simulation for target and biomarker discovery), and a Patent Extractor for
  mining antibody sequences. The platform is delivered to biotech and pharmaceutical customers under a Request Access engagement
  model; there is no public developer API, SDK, or self-serve documentation surface today. Backed by Bessemer Venture Partners
  ($25M Series A, January 2026); founded 2023.
url: https://raw.githubusercontent.com/api-evangelist/converge-bio/refs/heads/main/apis.yml
x-type: company
x-source: vc-portfolio
x-backed-by:
- bessemer-venture-partners
x-tier: stub
x-tier-reason: portfolio-lead
accessModel:
  pricing: unknown
  onboarding: approval
  trial: false
  try_now: false
  public: false
  label: Requires approval
  confidence: medium
  source: []
  generated: '2026-07-22'
  method: derived
specificationVersion: '0.20'
created: '2026-07-17'
modified: '2026-07-18'
image: https://framerusercontent.com/assets/3MosxeGKxrmsbR7VQX5B7ChJ5xg.png
tags:
- Company
- Ai Ml
- Drug Discovery
- Generative AI
- Biotech
- Pharmaceutical
- Antibody Design
- Genomics
- Life Sciences
- Machine Learning
apis: []
maintainers:
- FN: Kin Lane
  email: kin@apievangelist.com
- FN: APIs.json
  email: info@apis.io
common:
- type: DomainSecurity
  url: security/converge-bio-domain-security.yml
- type: LLMsTxt
  url: llms/converge-bio-llms.txt
- type: Website
  url: https://converge-bio.com/
- type: Blog
  url: https://converge-bio.com/blog
- type: Support
  url: https://converge-bio.com/contact
- type: TermsOfService
  url: https://converge-bio.com/docs/terms-of-use
- type: PrivacyPolicy
  url: https://converge-bio.com/docs/privacy-policy
- type: GitHubOrganization
  url: https://github.com/ConvergeBio
x-enrichment:
  date: '2026-07-19'
  status: backfilled
  pass: local-v1
  note: backfilled from .gitignore signal + verified work evidence